MedTrace Logo

The Clinical Trial to Evaluate the Efficacy and Safety of CKD-497

NCT03726853 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2020-02-06

No results posted yet for this study

Summary

To evaluate the efficacy and safety of CKD-497

Conditions

  • Respiratory Infection

Interventions

DRUG

CKD-497 200mg

CKD-497 200mg

DRUG

CKD-497 300mg

CKD-497 300mg

DRUG

CKD-497 placebo

Placebo of CKD-497

DRUG

Comparator

Comparator

DRUG

Comparator placebo

Comparator placebo

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-29
Primary Completion
2019-03-21
Completion
2019-03-21

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03726853 on ClinicalTrials.gov